Vimarsana
Biggest News Aggregation in the World

Coll Cardiol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Coll Cardiol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Coll Cardiol Today - Breaking & Trending Today

ARYA Sciences Acquisition IV : ADAGIO MEDICAL Investor Presentation | June 2024 1 Form 8 K - Vimarsana News

ARYA Sciences Acquisition IV : ADAGIO MEDICAL Investor Presentation | June 2024 1 Form 8 K

ADAGIO MEDICAL Investor Presentation | June 2024 1 DISCLAIMER This investor presentation is for informational purposes only to assist interested parties in making their...

Most Heart Disease Deaths Still Occur in Cold Weather, but Heat Is a Growing Problem - Vimarsana News

Most Heart Disease Deaths Still Occur in Cold Weather, but Heat Is a Growing Problem

Rising mortality burden from high ambient temperatures around the world

Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia - Vimarsana News

Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 Data presented at European Atherosclerosis Society 92nd Congress and

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM - Vimarsana News

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM

Treatment-Related Early Increase in Serum TTR is Associated With Lower Cardiovascular Mortality in ATTR-CM: Insights From ATTRibute-CM Amrut...

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia - Vimarsana News

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92nd Congress...